Chaudry I H
Department Surgery, Michigan State University, East Lansing 48823.
Prog Clin Biol Res. 1989;299:19-31.
The information available indicates that following hepatic ischemia and reflow, there is decreased tissue ATP levels, decreased tissue and mitochondrial magnesium levels, and decreased mitochondrial capability. Associated with these changes are altered cellular functions. Administration of ATP-MgCl2 following ischemia significantly improves total and microcirculatory blood flow, tissue and mitochondrial magnesium levels, tissue ATP stores, cellular functions, and the survival of animals. In contrast to ATP-MgCl2, administration of ATP or MgCl2 alone after ischemia was ineffective in improving cellular functions and tissue and mitochondrial magnesium levels. ATP-MgCl2 therefore appears to be a promising adjunct to the treatment of shock and ischemia.
现有信息表明,肝脏缺血再灌注后,组织ATP水平降低,组织和线粒体镁水平降低,线粒体功能下降。与这些变化相关的是细胞功能改变。缺血后给予ATP-MgCl2可显著改善总血流量和微循环血流量、组织和线粒体镁水平、组织ATP储备、细胞功能以及动物存活率。与ATP-MgCl2相反,缺血后单独给予ATP或MgCl2对改善细胞功能以及组织和线粒体镁水平无效。因此,ATP-MgCl2似乎是治疗休克和缺血的一种有前景的辅助药物。